Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice

International Journal of Hematology

Volumn 96, Issue 5, 2012, Pages 638-648

  Kagiyama, Yuki ^a   Kitaura, Jiro ^a   Togami, Katsuhi ^a   Uchida, Tomoyuk ^a   Inoue, Daichi ^a   Matsukawa, Toshihi ^a   Izawa, Kumi ^a   Kawabata, Kimihito C ^a   Komeno, Yukiko ^a   Oki, Toshihi ^a   Nakahara, Fumio ^a   Sato, Katsuak ^b   Aburatani, Hiroyuk ^c   Kitamura, Toshio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

AML; AML1 ETO; An active c Kit mutant; CD200R1

Indexed keywords

ARGININE; ATAXIN 1; CD200 RECEPTOR; CD200 RECEPTOR 1; FLUOROURACIL; FUSION PROTEIN AML1 ETO; GLUTAMINE; HYBRID PROTEIN; SERINE; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VALINE;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CELL LINEAGE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; LEUKEMIA CELL; LEUKEMIC STEM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, LEUKEMIC; LEUKEMIA; MICE; MUTATION, MISSENSE; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RATS; RECEPTORS, CELL SURFACE; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84872202150     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1207-6     Document Type: Article

References (39)

1. Watanabe-Okochi Naoko, Kitaura Jiro, Ono Ryoichi, Harada Hironori, Harada Yuka, Komeno Yukiko, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008;111:4297-308.
2. Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood. 2007;110:799-805.
3. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol. 2011;94:126-33.
4. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA. 1991;88:10431-4.
5. Erickson P,Gao J,Chang KS,Look T, WhisenantE,Raimondi S, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80:1825-31.
6. Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91:3134-43.
7. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-30.
8. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet. 1997;15:303-6.
9. HiguchiM, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes amurine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63-74.
10. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ, et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 2000;96:2108-15.
11. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA. 1998;95:10860-5.
12. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressorhistone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:7185-91.
13. Nick HJ, Kim HG, Chang CW, Harris KW, Reddy V, Klug CA. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia. Blood. 2012;119:1522-31.
14. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA. 2005;102:1104-9.
15. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, et al. KIT-D816 mutations in AML1-ETOpositive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-9.
16. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol. 2007;27:267-82.
17. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. 1995;85:790-8.
18. Gilliland DG. Hematologic malignancies. Curr Opin Hematol. 2001;8:189-91.
19. Hoang VT, Zepeda-Moreno A, Ho AD. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance. Biotechnol J. 2012;7:779-88.
20. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres- Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-8.
21. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-84.
22. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104: 11008-13.
23. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286-99.
24. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138: 271-85.
25. Aikawa Y, Katsumoto T, Zhang P, Shima H, Shino M, Terui K, et al. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat Med. 2010;16:580-5.
26. Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7: 708-17.
27. Cherwinski HM, Murphy CA, Joyce BL, Bigler ME, Song YS, Zurawski SM, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol. 2005;174:1348-56.
28. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003;171:3034-46.
29. Yamanishi Y, Kitaura J, Izawa K, Matsuoka T, Oki T, Lu Y, et al. Analysis of mouse LMIR5/CLM-7 as an activating receptor: differential regulation of LMIR5/CLM-7 in mouse versus human cells. Blood. 2008;111:688-98.
30. Doki N, Kitaura J, Uchida T, Inoue D, Kagiyama Y, Togami K, et al. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models. Int J Hematol. 2012;95:167-75.
31. Nakahara F, Sakata-Yanagimoto M, Komeno Y, Kato N, Uchida T, Haraguchi K, et al. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood. 2010;115:2872-81.
32. Kato N, Kitaura J, Doki N, Komeno Y, Watanabe-Okochi N, Togami K, et al. Two types of C/EBPa mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood. 2011;117:221-33.
33. Sato K, Eizumi K, Fukaya T, Fujita S, Sato Y, Takagi H, et al. Naturally occurring regulatory dendritic cells regulate murine cutaneous chronic graft-versus-host disease. Blood. 2009;113: 4780-9.
34. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7:1063-6.
35. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol. 2003;31:1007-14.
36. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115:2159-68.
37. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6:587-96.
38. Dentesano G, Straccia M, Ejarque-Ortiz A, Tusell JM, Serratosa J, Saura J, et al. Inhibition of CD200R1 expression by C/EBP beta in reactive microglial cells. J Neuroinflammation. 2012;9:165.
39. Rochford JJ, Semple RK, Laudes M, Boyle KB, Christodoulides C, Mulligan C, et al. ETO/MTG8 is an inhibitor of C/EBPbeta activity and a regulator of early adipogenesis. Mol Cell Biol. 2004;24:9863-72.